although the fact that there are a number of patients still in follow-up is promising. I'm more commenting on that there is not any great data in this announcement. But the initial increase in the after hours US price shows that someone likes it (although I never trust the after hours market)
Ann: Kazia presents PK data for paxalisib at AACR meeting, page-3
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)